| Title | Rofecoxib administration induces alterations of biochemical indicators in rat serum | |
| Authors | D. Kouvelas¹, C. Pourzitaki¹, E. Delvizi², P. Skepastianos³, E. Andreadou³ and H. Tsoukali²
Laboratories of 1. Pharmacology and 2. Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 3. Medical Laboratories, Alexandreion T.E.I. of Thessaloniki, Greece |
|
| Citation | Kouvelas, D., Pourzitaki, Ch., Delvizi, E., Skepastianos, P., Andreadou, E. et al: Rofecoxib administration induces alterations of biochemical indicators in rat serum, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 235-237 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Rofecoxib, biochemical indicators, rat serum. | |
| Other Terms | review article | |
| Summary | Cyclooxygenase-2 (COX-2) is the mainly inducible, pro-inflammatory COX-isoform. COX-2 selective inhibitors have been accused of increasing risk of cardio- vascular complications due to their vasoconstrictive and thrombogenic actions (1,2). The purpose of the present study was to investigate the influence of a COX-2 inhibitor on the classic biochemical indicators of cardiovascular and metabolic dysfunction. Rofecoxib was administered in male Wistar rats (25 mg/Kg, s.c.) and the levels of cholesterol, triglycerides, SGOT, SGPT, CPK, CRP and troponin were measured in blood samples. Our results indicate that rofecoxib causes statistically significant biochemical changes, in rat blood serum which are time dependent. The above changes are indicating that the administration of COX-2 inhibitors is related with increased risk, developed in time, of serious cardiovascular events. | |
| References | 1. Mitchell J.A., Warner T.D.: Cyclooxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. 128: 1121-1132 (1999)
2. Rong W., Laplante M.A., Champlain J.: Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension and cardiac hypertrophy in rats. Hypertension 45: 1139 (2005) 3. Mukherjee D., Nissen S.E., Topol E.J.: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959 (2001) 4. Buerkle M.A., Selim L., Sohn H.Y., Conzen P., Pohl U., Krotz F.: Selective inhibition of cycloxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 110: 2053-59 (2004) 5. Ringler D.H., Dabich L.: Hematology and clinical biochemistry in the laboratory rat. Pp. 105-121, Academic Press New York, 1979 6. Brideau C., Kargman S., Lin S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.C.: A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxybenase inhibitors. Inflam. Res. 45: 68-74 (1996) 7. Cheng Y., Austin S.C., Rocca B., Koller B.H, Coffman T.M., Grosser T.L., Fitzerald J.A. Garret A.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567): 539-541 (2002) 8. Patrono C., Ciabattoni G., Patrignani P., Pugliese F., Filabozzi P., Catella F., Davi G., Forni L.: Clinical Pharmacology of platelet cycloxygenase inhibition. Circulation 72: 1177-1184 (1985) 9. Fosslien E.: Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann. Clin. Lab. Sci. 35: 347-385 (2005) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|